Convergent raises $90M to develop its radiopharmaceutical for prostate cancer
News & media
Radioantibody startup led by prostate cancer experts raises $90M
Cambridge biotech raises $90 million for drug that uses radioactive atoms to fight prostate cancer
Radiopharmaceutical company Convergent closes series A to the tune of $90M
May 3 Quick Takes: Clinical-stage targeted radio-antibody newco Convergent raises $90M A round
Six-person Cornell spinout raises $90M for prostate cancer drugs
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC
Convergent Therapeutics, Inc. Next Generation Radiopharmaceutical Therapies for Prostate – Philip Kantoff
Developing Next-Generation Radiopharmaceuticals
ESMO 2022: Advances in the Treatment of Cancer